Welcome to our dedicated page for Ideaya Biosciences SEC filings (Ticker: IDYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IDEAYA Biosciences, Inc. filings document the regulatory record of a Nasdaq-listed precision oncology company developing targeted therapeutics and biomarker-directed cancer programs. Recent 8-K reports cover financial results, business updates, clinical data from the OptimUM darovasertib program, collaboration agreements involving investigational oncology assets, and Regulation FD corporate presentations.
The company’s SEC record also includes proxy materials for annual meeting governance, executive compensation and equity-plan matters. Registration and prospectus filings describe IDEAYA’s common stock, automatic shelf registration capacity, at-the-market sales arrangements and related capital-structure disclosures, alongside risk and pipeline information tied to its clinical-stage oncology portfolio.
IDEAYA Biosciences director Wendy L. Yarno received a grant of stock options for 20,000 shares of common stock at an exercise price of $30.57 per share. The options vest 100% on the earlier of one year from grant or immediately before the next Annual Meeting, subject to continued Board service, and expire on June 16, 2036.
IDEAYA Biosciences director Jeffrey Stein received a grant of stock options to acquire 20,000 shares of common stock at an exercise price of $30.57 per share. These options expire on June 16, 2036 and are intended as equity-based compensation.
According to the terms, 100% of the shares subject to the option will vest on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting following the grant date, provided he continues serving on the board through the vesting date.
IDEAYA Biosciences director Terry J. Rosen received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $30.57 per share and expire on June 16, 2036. According to the footnote, 100% of the option vests on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, if he continues serving on the Board until that vesting date.
IDEAYA Biosciences director Scott W. Morrison received a grant of stock options for 20,000 shares of Common Stock. The options have an exercise price of $30.57 per share and expire on June 16, 2036. All 20,000 shares vest on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, if he remains on the Board through that date.
This is a compensation-related award, not an open-market purchase or sale, and leaves him with 20,000 derivative securities reported after the transaction.
IDEAYA Biosciences director Catherine J. Mackey received a stock option grant covering 20,000 shares of Common Stock. The option has an exercise price of $30.57 per share and expires on June 16, 2036. All 20,000 option shares vest on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, if she continues serving on the Board.
IDEAYA Biosciences, Inc. director Malcolm Garret Hampton received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of $30.57 per share and expire on June 16, 2036.
All 20,000 options vest in full on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting following the grant, as long as he continues serving on the board through the vesting date. This filing reflects a compensation-related award rather than an open-market trade.
IDEAYA Biosciences, Inc. completed a sizable equity offering under an underwriting agreement with multiple investment banks. The company sold 7,222,225 shares of common stock, including full exercise of the underwriters’ 1,666,669-share option, and issued pre-funded warrants to purchase 5,555,576 additional shares. The public offering price was $27.00 per share and $26.9999 per pre-funded warrant, with the underwriters purchasing at discounted prices of $25.38 and $25.3799, respectively. IDEAYA reports net proceeds of approximately $323.6 million, after underwriting discounts and estimated expenses, providing substantial new capital for the business. Directors, executive officers and the company agreed to a 60-day lock-up on most share sales, and the securities were issued off an automatically effective shelf registration statement on Form S-3.
IDEAYA Biosciences is offering 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares of common stock. The public offering price is $27.00 per share and $26.9999 per pre-funded warrant, with estimated net proceeds of approximately $281.3 million before expenses. The underwriters have a 30-day option to purchase up to 1,666,669 additional shares. The prospectus supplement states proceeds are intended to fund continued clinical development and potential commercialization of darovasertib, advancement of the company’s pipeline and general corporate purposes.
IDEAYA Biosciences, Inc. is offering $300,000,000 of common stock and, in lieu of shares to certain investors, pre-funded warrants exercisable at $0.0001 per share, with an underwriter option to purchase an additional $45,000,000 of common stock.
The prospectus supplement is part of a shelf registration and ties the offering to proceeds intended for continued clinical development and potential commercialization of darovasertib, advancement of the company’s precision oncology pipeline, and general corporate purposes. The document discloses 87,856,154 shares outstanding as of March 31, 2026 and reports a historical net tangible book value of $937.3 million (or $10.67 per share) as of that date.
IDEAYA Biosciences, Inc. is offering $300,000,000 of common stock and, in lieu of shares to certain investors, pre-funded warrants exercisable at $0.0001 per share, with an underwriter option to purchase an additional $45,000,000 of common stock.
The prospectus supplement is part of a shelf registration and ties the offering to proceeds intended for continued clinical development and potential commercialization of darovasertib, advancement of the company’s precision oncology pipeline, and general corporate purposes. The document discloses 87,856,154 shares outstanding as of March 31, 2026 and reports a historical net tangible book value of $937.3 million (or $10.67 per share) as of that date.
IDEAYA Biosciences, Inc. reported the initial equity holdings of Chief Development Officer Theodora Ross on a Form 3. She holds a stock option to purchase common stock with an exercise price of $31.90 per share, covering 297,200 underlying shares, expiring on February 26, 2036.
According to the vesting terms, 25% of the shares vest on the first anniversary of the February 23, 2026 vesting commencement date, and the remaining shares vest in equal monthly installments over the following three years until fully vested.